CRMD News and Press, CorMedix Inc. From 09/17/20

BERKELEY HEIGHTS, N.J., Sept. 17, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced the appointment...

BERKELEY HEIGHTS, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that CorMedix m...

NGM Bio reports positive Phase 2 data for Aldafermin NGM Biopharmaceuticals Inc. ( NGM ) reported final data from its 24-week Phase 2 study of aldafermin 1 mg. The trial involved patients with non-alcoholic steatohepatitis. The readout included a new analysis of data gathered from Cohort...

FDA has accepted CorMedix (NYSEMKT: CRMD ) +7% filing of new drug application for Defencath its product candidate to be used as a catheter lock solution in hemodialysis patients for the prevention of catheter related blood stream infections. More news on: CorMedix Inc., Stocks on the m...

Aimmune Therapeutics (NASDAQ: AIMT ) +171%  on being acquired by Nestle. More news on: Aimmune Therapeutics, Inc., Akcea Therapeutics, Inc., Genworth Financial, Inc., , , Read more ...

FDA sets PDUFA goal date of February 28, 2021 Potentially the first antibacterial and antifungal catheter lock solution in the US to prevent catheter related infections in hemodialysis patients  BERKELEY HEIGHTS, N.J., Aug. 31, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE Amer...

CorMedix (NYSEMKT: CRMD ) director Mehmood Khan purchased a total of 45750 shares on August 18 and 19, making total share holding of 178,767 shares. More news on: CorMedix Inc., Stocks on the move, Healthcare stocks news Read more ...

CorMedix Inc. (CRMD) Q2 2020 Earnings Conference Call August 10, 2020 4:30 PM ET Company Participants Dan Ferry – Managing Director-LifeSci Advisors Khoso Baluch – Chief Executive Officer Phoebe Mounts – Executive Vice President and General Counsel Matt Dav...

CorMedix (NYSEMKT: CRMD ) : Q2 GAAP EPS of -$0.14 in-line. More news on: CorMedix Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

BERKELEY HEIGHTS, N.J., Aug. 10, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced financial result...